Population PK & Dosing Implications for Cobimetinib in Cancer Patients

A population pharmacokinetic model was developed for cobimetinib in cancer patients. Covariates had minimal impact on steady-state exposure, suggesting no need for dose adjustments and supporting the recommended
dose for all patients.

Author(s): Kelong Han, Jin Jin, Mathilde Marchand, Stephen Eppler, Nicholas Choong, Stephen Hack, Nalin Tikoo, Rene Bruno, Mark Dresser, Luna Musib, Nageshwar Budha

Year: November 1, 2015